IASO Bio's Equecabtagene Autoleucel for Refractory Myastheni

/PRNewswire/ -- On February 26, 2024, the impactful international academic journal, EMBO Molecular Medicine, published the clinical data of the fully human...

Related Keywords

Huazhong , Hubei , China , Tongji , Sichuan , Shanghai , Nanjing , Jiangsu , Wei Wang , Gansu , Equecabtagene Autoleucel , Demyelinating Polyneuropathy , China National Medical Products Administration , Huazhong University Of Science , Tongji Medical College , Acetylcholine Receptor , Lipoprotein Receptor Related Protein , Ryanodine Receptor , Tongji Hospital , Huazhong University , Release Syndrome , Cell Associated Neurotoxicity Syndrome , Myasthenia Gravis Activities , Daily Living Score , Quantitative Myasthenia Gravis Score , Myasthenia Gravis Quality , Life Score , Modified Rankin Score , Myasthenia Gravis , Immune Mediated Necrotizing Myelopathy , Chronic Inflammatory Demyelinating Polyneuropathy , New Drug Application , National Medical Products Administration ,